In vivo CAR T-cell therapy: a systematic review of clinical trials
In vivo chimeric antigen receptor (CAR) T-cell therapy directly programs endogenous T cells within the patient rather than generating the cells through conventional ex vivo manufacturing. While promising, the clinical landscape of this emerging technology is fragmented. Therefore, this systematic review evaluated...